Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.Lindsey Fitzgerald, Boyu Hu, Adam S. Kittai et al.|Journal of Clinical Oncology|2020Cited by 19
Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US CentersEmily C. Ayers, Narendranath Epperla, Viktoriya Zelikson et al.|Blood|2023Cited by 10
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centersViktoriya Zelikson, Emily C. Ayers, Ashwath Gurumurthi et al.|Haematologica|2024Cited by 6
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers.Jennifer Santos, Jason T. Romancik, Loretta J. Nastoupil et al.|UNC Libraries|2024Cited by 0
Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphomaPierre Stéphan, Jennifer L. Crombie, Karan Chohan et al.|Blood|2025Cited by 0